Latest filing published 03 Mar 2026 for Organogenesis Holdings Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Antonio S. Montecalvo (senior executive) discloses dealings in Organogenesis Holdings Inc. to SEC (Form 4). Over a trading history stretching from 10 December 2018 to 18 February 2026, the count stands at 35 filings.
The open-market record consists of 2 sales worth €816k, with no purchase. Outside the open market, there are 30 share grants and 3 option exercises.
On 3 March 2026 came the latest disclosure, a share grant for €12k in Organogenesis Holdings Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations